INS and gestational diabetes: In 2019, Lu and coworkers [143] analyzed the relationships between visfatin and GDM and observed significantly higher maternal serum visfatin concentrations for both analyzed sub-cohorts, namely diet (G1)- and insulin (G2)-treated GDM (50.7 ± 14.2 ng/mL and 48.5 ± 14.5 ng/mL, respectively) in comparison to the non-GDM cohort (31.1 ± 7.5 ng/mL).